药捷安康-B今日盘中大跌5.22%，引起了市场的广泛关注。
消息面上，公司于交易时段前宣布，拟以每股40.83港元的价格配售383.6万股新H股，配售价较前一交易日收盘价折让约18.01%，预计净筹资约1.52亿港元。折价配售新股通常会对二级市场股价造成短期压力，因稀释效应及较低的配售价可能影响投资者信心。
根据公告，此次配售所得款项净额约90%将用于公司核心产品Tinengotinib新适应症的开发，其余10%用于营运资金及一般企业用途。
药捷安康-B今日盘中大跌5.22%，引起了市场的广泛关注。
消息面上，公司于交易时段前宣布，拟以每股40.83港元的价格配售383.6万股新H股，配售价较前一交易日收盘价折让约18.01%，预计净筹资约1.52亿港元。折价配售新股通常会对二级市场股价造成短期压力，因稀释效应及较低的配售价可能影响投资者信心。
根据公告，此次配售所得款项净额约90%将用于公司核心产品Tinengotinib新适应症的开发，其余10%用于营运资金及一般企业用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.